XEPI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XEPI (XEPI).
Ozenoxacin is a topical fluoroquinolone antibiotic that inhibits bacterial DNA replication by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, leading to cell death.
| Metabolism | Systemic absorption is minimal; metabolism in systemic circulation is negligible. If absorbed, it is not extensively metabolized. |
| Excretion | Approximately 80% eliminated renally as unchanged drug via glomerular filtration and tubular secretion. Approximately 20% eliminated in feces via biliary excretion. |
| Half-life | Terminal elimination half-life is approximately 8 hours in patients with normal renal function (creatinine clearance ≥90 mL/min). In moderate renal impairment (CrCl 30-59 mL/min), half-life extends to about 15 hours. |
| Protein binding | Approximately 30% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.2-0.3 L/kg, indicating primarily extracellular fluid distribution with limited tissue penetration. |
| Bioavailability | Intravenous: 100% bioavailable. Oral bioavailability not applicable as drug is only administered intravenously. |
| Onset of Action | Intravenous administration: Clinical effect (bactericidal activity) within 30 minutes; tissue distribution rapid. |
| Duration of Action | Duration of bactericidal activity approximately 12-24 hours, supporting once-daily dosing in most infections. Prolonged in renal impairment. |
Topical: Apply a pea-sized amount to the affected area twice daily. For moderate to severe plaque psoriasis, initiate treatment with clobetasol propionate spray 0.05% applied twice weekly (Sunday and Thursday) to the scalp and/or body lesions. For plaque psoriasis under occlusion or on limited areas, clobetasol propionate foam 0.05% applied twice daily. For scalp psoriasis, clobetasol propionate shampoo 0.05% applied once daily to the dry scalp, left for 15 minutes, then rinsed. For steroid-responsive dermatoses, clobetasol propionate ointment, cream, or lotion 0.05% applied sparingly to the affected area twice daily (morning and night) for up to 2 weeks; re-evaluate if no improvement. Maximum dose: 50 g/week of 0.05% preparation; for scalp applications, 50 mL/week.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment is required in patients with renal impairment as topical absorption is minimal. Systemic toxicity is unlikely, but caution is advised in severe renal impairment due to potential accumulation of excipients. For oral formulations (not applicable), no data available. |
| Liver impairment | No dosage adjustment is required in patients with hepatic impairment based on low systemic absorption. However, in severe hepatic impairment (Child-Pugh C), systemic corticosteroid effects may be potentiated; use with caution and limit application area. For oral formulations (not applicable), no data available. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. Use is not recommended for children under 12 years of age due to higher risk of hypothalamic-pituitary-adrenal axis suppression. For children 12-17 years, apply the same dose as adults but limit treatment to 2 weeks; do not use under occlusion; avoid face, axillae, and groin. Maximum duration: 2 consecutive weeks. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for XEPI (XEPI).
| Breastfeeding | Cefepime is excreted into human milk in small amounts (M/P ratio approximately 0.03-0.05); enmetazobactam is likely excreted similarly but data are lacking. The low milk concentrations suggest minimal risk to a nursing infant, but caution is advised due to potential alteration of infant gut flora. The American Academy of Pediatrics considers cefepime compatible with breastfeeding. |
| Teratogenic Risk | XEPI (cefepime, enmetazobactam) is classified as Pregnancy Category B based on animal studies. There are no adequate and well-controlled studies in pregnant women. For trimester 1, 2, and 3, the potential risk to the fetus is considered low based on animal data, but the drug should only be used if clearly needed. No specific teratogenic patterns have been identified. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to ozenoxacin or any component of the formulation, or to other fluoroquinolones."]
| Precautions | ["Hypersensitivity reactions including anaphylaxis have been reported. Discontinue if rash or other allergic symptoms occur. Avoid prolonged use as it may result in overgrowth of non-susceptible organisms including fungi. For external use only; not for ophthalmic, oral, or intravaginal use."] |
Loading safety data…
| Geriatric use | No specific dose adjustment is needed, but elderly patients may have increased susceptibility to topical corticosteroid adverse effects due to age-related skin thinning. Use the lowest effective dose for the shortest duration. Monitor for skin atrophy, telangiectasias, and systemic absorption. Avoid use on large areas or under occlusion. Apply sparingly and discontinue if irritation occurs. |
| Fetal Monitoring | Monitor for maternal hypersensitivity reactions, diarrhea (C. difficile colitis), and changes in renal function. Fetal monitoring is not specifically required, but standard obstetric monitoring is recommended during treatment of maternal infections. For prolonged therapy, monitor for signs of neutropenia or superinfection. |
| Fertility Effects | Animal studies with cefepime and enmetazobactam have not shown adverse effects on fertility or reproductive performance. No human data are available. The potential for reversible impairment of spermatogenesis is not evaluated, but based on beta-lactam class effects, impact on fertility is unlikely. |